HT CAPITAL
HT Capital, an establishment under Hongtao (HT) Asset Management has been actively investing since 1999. The management team, based between Beijing and Hong Kong covers a full-spectrum of investment activities and strategic portfolio managements in varies sectors including Healthcare, IT and the TMT industry.
HT CAPITAL
Status:
Active
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2022-01-03 | Kula Bio | HT Capital investment in Series A - Kula Bio | 50 M USD |
| 2021-09-13 | Alebund Pharmaceuticals | HT Capital investment in Series B - Alebund Pharmaceuticals | 54.5 M USD |
| 2021-08-01 | JOINN Biologics | HT Capital investment in Series B - JOINN Biologics | 150 M USD |
| 2021-06-01 | Inmagene Biopharmaceuticals | HT Capital investment in Series C - Inmagene Biopharmaceuticals | 100 M USD |
| 2020-09-25 | LeJian | HT Capital investment in Series A - LeJian | N/A |
| 2020-09-09 | LandSpace | HT Capital investment in Series C - LandSpace | 1.2 B CNY |
| 2020-04-04 | Kringle Pharma | HT Capital investment in Venture Round - Kringle Pharma | 740 M JPY |
| 2019-07-19 | TriArm Therapeutics | HT Capital investment in Series A - TriArm Therapeutics | 20 M USD |
| 2019-05-27 | Kyulux | HT Capital investment in Series B - Kyulux | 3.5 B JPY |
| 2018-10-25 | XtalPi | HT Capital investment in Series B - XtalPi | 46 M USD |